Financial PerformanceTarsus Pharmaceuticals reported Q1 2025 revenues of $78.3M compared to $24.7M in the same period in 2024, indicating significant growth.
Market CoverageThe company has broad commercial coverage with Medicare and Medicaid reimbursement and more than 90% of covered lives, addressing prescriber apprehension regarding coverage pushback.
Product AdoptionThe ease of diagnosis and outstanding efficacy and safety profile of Xdemvy contributed to its rapid adoption among eye care professionals.